AbbVie Inc. announced that SKYRIZI met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx in a head-to-head Phase 3 study. SKYRIZI showed significantly higher rates of skin clearance compared to Cosentyx, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Of patients treated with SKYRIZI, 87% achieved PASI 90 compared to 57% of Cosentyx-treated patients at 52 weeks (p<0.001). At week 16, SKYRIZI also met the other primary endpoint of non-inferiority to Cosentyx with 74% of SKYRIZI patients achieving PASI 90 compared to 66% of Cosentyx patients. SKYRIZI also showed superiority compared to Cosentyx for all ranked secondary endpoints, including PASI 100, and PASI 75, as well as a static Physician Global Assessment score of clear or almost clear (sPGA 0/1) at week 52 (p<0.001). Current safety data available demonstrated that the safety profile of SKYRIZI was consistent with that observed in previously reported studies, with no new safety signals observed through week 52. The rates of adverse events (AEs) were comparable between SKYRIZI and Cosentyx. The most common AEs were nasopharyngitis, upper respiratory tract infection, headache, arthralgia and diarrhea. The rate of serious AEs were 5.5% in the SKYRIZI group and 3.7% in the Cosentyx group. Adverse events leading to discontinuation of the study drug were 1.2% in the SKYRIZI group and 4.9% in the Cosentyx group. There were no deaths in either treatment group.